Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by linpawson Jun 12, 2020 2:35pm

154 Views

Post# 31144520

RE:TSX.V RING EXPOSED - AGHANADA EXCHANGE

mstrmnd, get off the rhetoric. You are a small fish in a massive pond. So you aren't going to get anywhere with this. I would suggest you keep the discussion to analysis of the stock rather than continuing your rant on insider selling. Management aren't stupid so risk their entire working lives to do insider trading.

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal